Proven Impact at Scale
The $13B "Manual Tax"
Current centralized Quality Control infrastructure cannot support the velocity of decentralized, personalized medicines. We must move Quality Control inside the Manufacturing Suite.
The Failure Point
Patients wait. Therapies expire. Costs explode.
Hardware-Enabled SaaS
One-Time CapEx • GMP Consumables • Annual Platform Licensing
The Edge PAT Skid
"QC on Wheels". Mobile hardware bringing analytical insights into production. Enables simultaneous in-line multi-attribute analysis using Single-Use Flow Paths (GMP Requirement).
Learn MoreDigital OS
The prescriptive intelligence layer being built now. Includes Chemometrician AI — a real, prototyped capability for quantitative spectral model development — and pre-built regulatory-accepted models, so no PhD-level scientist is required on-site.
Learn MoreCMC Intelligence
Closed-loop vision: digital twins that de-skill the lab. Predictive analytics for yield optimization and autonomous process intelligence across the site — same validated tools everywhere, no tech transfer.
Learn MoreThe Regulatory Moat
Competitors sell hardware. We sell a Pre-Validated Regulatory Pathway.
$82M CBER Program
FDA CBER partnership to validate PAT tools as "Release Methods" — the highest regulatory endorsement available.
Type II DMF Strategy
Customers reference our DMF to treat the machine as a pre-approved "Drug Substance Engine."
76% CQA Coverage
Covered real-time. In-line results match offline analytics (<5% RSD).